RxDoctor Payments Data

Jayme Davis-Waddell, NP

Family · Bowling Green, KYNPI 1992120075

Payments from drug & device makers

$8,294in general payments, 2019–2025

Across 559 payments — averaging $14.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$805
  • Amgen$724
  • Bayer$691
  • Novartis$659
  • Pfizer$636
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,294100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,294 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$104,964
Medicare patients
445
Services billed
6,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$65,303
JardianceEmpagliflozin36$52,514
JanuviaSitagliptin Phosphate44$50,583
FarxigaDapagliflozin Propanediol38$42,015
EliquisApixaban24$23,307
XareltoRivaroxaban11$16,953
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,044
VraylarCariprazine Hcl11$15,637
RybelsusSemaglutide23$15,117
MyrbetriqMirabegron16$10,604
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,041
BrilintaTicagrelor12$5,108
Desvenlafaxine Succinate ErDesvenlafaxine Succinate43$3,997
Albuterol Sulfate HfaAlbuterol Sulfate88$2,108
SynthroidLevothyroxine Sodium26$1,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$805$80,42078 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$415$55,16464 claims
Boehringer IngelheimJardiance$319$52,51436 claims
PfizerEliquis$636$23,30724 claims
AbbVieVraylar, Synthroid, Armour Thyroid$1,195$19,31153 claims
Johnson & JohnsonXarelto$181$16,95311 claims
GSKTrelegy Ellipta$218$16,04424 claims
Astellas Pharma US IncMyrbetriq$90$10,60416 claims
Acella Pharmaceuticals, LLCNp Thyroid$30$1,22917 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$63$1,013147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →